|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we identify constitutively activated ERK in almost all melanoma cell lines and in tumor tissues tested, which is in contrast to normal melanocytes and several early stage radial growth phase melanoma lines where ERK can be activated by serum or growth factors.
|
12591721 |
2003 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, ectopic expression of dominant-active MEK in this melanoma cell line conferred UV(B) resistance suggesting that the ERK/MAPK pathway downstream of DCT may play a critical role in radiation and drug resistance.
|
14712208 |
2004 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hierarchical clustering analysis of the expression data was able to distinguish between the melanoma and nonmelanoma samples and further stratified the melanoma samples into two groups differentiated by high expression of the genes involved in beta-catenin activation (EGFR and WNT5A) and the MAPK/ERK pathway (BRAF, FOS, and JUN).
|
16116595 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results provide strong evidence for another mode by which BRAF can regulate the ERK protein kinase family and suggest ERK3 to be a potential pharmacodynamic marker for targeting BRAF signaling in melanoma.
|
16964379 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The RAS/BRAF/MEK/ERK mitogen-activated protein kinase (MAPK) pathway is emerging as a key modulator of melanoma initiation and progression.
|
17145881 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.
|
17245336 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we examined whether targeting the MAPK and/or AKT signalling pathways would have therapeutic effects against melanoma.
|
17388918 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Employing 2 independent, genome-wide microarray analyses, we identified CD200 as a highly dynamic, downstream target of RAS/RAF/MEK/ERK activation in melanoma.
|
18008004 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we examined whether targeting the RAS-RAF-MEK-ERK pathway with the RAF inhibitor sorafenib and/or the PI3K-AKT-mTOR pathway with the mTOR inhibitor rapamycin has therapeutic effects against melanoma.
|
18323781 |
2008 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistent with this, inhibition of ERK activity in a panel of melanoma cell lines resulted in stabilization of Bim and dephosphorylation of Bad.
|
18508762 |
2008 |
|
melanoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
PD0325901 markedly inhibited ERK phosphorylation and growth of both BRAF mutant and wild-type melanoma cell lines, with IC(50) in the nanomolar range even in the least responsive models.
|
19649202 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oncogenic mutations in BRAF are common in melanoma and drive constitutive activation of the MEK/ERK pathway.
|
19682280 |
2009 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When expressed in rat pheochromocytoma cell line cells, the R151C, R160W and D294H MC1R variants associated with melanoma and impaired cAMP signalling mediated ERK activation and ERK-dependent, agonist-induced neurite outgrowth comparable with wild-type.
|
19755124 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma.
|
19895547 |
2010 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The protein levels of hnRNP K and p-ERK in 8 human melanoma cell lines and a melanoma progression tissue microarray containing 80 melanoma, 23 dysplastic nevi, and 14 benign nevi specimens were analyzed using Western blot and immunohistochemistry analysis. hnRNP K was knocked down by siRNA, and its effect on melanoma cells was assessed.
|
20499280 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that melanoma metastasis is a molecularly heterogeneous process that may not require epithelial-to-mesenchymal transition or ERK activation, although both may facilitate the process.
|
20679910 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Utilisation of the PI3K-PKB, MEK-ERK and mTOR-p70S6K signalling pathways in melanoma, as determined by phosphorylation of signalling components, varies widely across a series of cell lines, and does not directly reflect mutation of genes coding these components.
|
22475322 |
2012 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Raf inhibitors are clinically highly effective for the treatment of cancer and melanoma in particular, but have unexpected side effects that include a paradoxical activation of the ERK pathway.
|
23212737 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, our in vitro studies showed a remarkable increase of cell migration and stress fiber formation in Fbw7 knockdown cells, and treatment of selective MEK (MAPK/ERK kinase) inhibitor abrogated Fbw7α knockdown-induced melanoma cell migration.
|
23381582 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this report, we identified a solid role for mda-7/IL-24 in invasion inhibition of human melanoma cancer LiBr cells, including decreasing of adhesion and invasion in vitro, blocking cell cycle, down-regulating the expression of ICAM-1, MMP-2/9, CDK1, the phosphorylation of ERK and Akt, NF-κB and AP-1 transcription activity.
|
23772146 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Such an increase was also observed by immunohistochemistry in melanoma specimens as compared with nevi, and occurred downstream of ERK activation because of BRAF or NRAS mutations.
|
23893239 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma is a disease characterized by lesions that activate ERK.
|
24576830 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that BRAF inhibition induces invasion and metastasis in RAS mutant melanoma cells through a mechanism mediated by the reactivation of the MEK (mitogen-activated protein kinase kinase)-ERK pathway, increased expression and secretion of interleukin 8, and induction of protease-dependent invasion.
|
24667377 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serine threonine kinases BRAF and MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] are major regulators of the ERK/MAPK pathway, which is deregulated in the majority of melanomas.
|
25109949 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Ras/Raf/MEK/ERK pathway has been identified as a major, druggable regulator of melanoma.
|
25294877 |
2014 |